Company profile
Palvella Therapeutics, Inc.
NASDAQ: PVLA · Healthcare · Biotechnology
#472 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
54DFH 47DQ 57GM 68SS 61
v0.1 · 65/100 weight · provisional
↑ Altman-Z, market scale · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$41.7M
Employees
29
as of 2026-08-09
Market cap
$2.3B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$38.7M$38.7M2023
Net income-$41.7M-$41.7M2025
Operating income-$38.6M-$38.6M2025
Total assets$59.6M$59.6M2025
Liabilities$31.6M$31.6M2025
Equity$28.0M$28.0M2025
Revenue trend
FY2016 – FY2023 · USD
FY16
FY17
FY19
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Palvella Therapeutics, Inc.’s revenue?
Palvella Therapeutics, Inc. booked $38.7M in FY2023 revenue, growing 52% year over year — faster than most Healthcare companies we track, at a -107.8% net margin.
Peers · Healthcare
Big Tree Group, Inc.——Kymera Therapeutics, Inc.53DInterpace Biosciences, Inc.74BUtah Medical Products, Inc.80B+Retractable Technologies, Inc.57CCytosorbents Corporation55CNeighbors
Delaware →Key facts
CEOWesley H. Kaupinen
SectorHealthcare
IndustryBiotechnology
HeadquartersWayne, PA
ExchangeNASDAQ: PVLA
Employees29
IPO date2015-01-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.